Pilot study of chronic maternal hyperoxygenation and effect on aortic and mitral valve annular dimensions in fetuses with left heart hypoplasia.

OBJECTIVE: Acute maternal hyperoxygenation (AMH) results in increased fetal left heart blood flow. Our aim was to perform a pilot study to determine the safety, feasibility and direction and magnitude of effect of chronic maternal hyperoxygenation (CMH) on mitral and aortic valve annular dimensions in fetuses with left heart hypoplasia (LHH) after CMH. METHODS: Gravidae with fetal LHH were eligible for inclusion in a prospective evaluation of CMH. LHH was defined as: sum of aortic and mitral valve annuli Z-scores < -4.5, arch flow reversal and left-to-right or bidirectional atrial level shunting without hypoplastic left heart syndrome or severe aortic stenosis. Gravidae with an affected fetus and with ≥ 10% increase in aortic/combined cardiac output flow after 10 min of AMH at 8 L/min 100% fraction of inspired oxygen were offered enrollment. Nine gravidae were enrolled from February 2014 to January 2015. The goal therapy was ≥ 8 h daily CMH from enrollment until delivery. Gravidae who were cared for from July 2012 to October 2014 with fetal LHH and no CMH were identified as historical controls (n = 9). Rates of growth in aortic and mitral annuli over the final trimester were compared between groups using longitudinal regression. RESULTS: There were no significant maternal or fetal complications in the CMH cohort. Mean gestational age at study initiation was 29.6 ± 3.2 weeks for the intervention group and 28.4 ± 1.8 weeks for controls (P = 0.35). Mean relative increase in aortic/combined cardiac output after AMH was 35.3% (range, 18.1-47.9%). Median number of hours per day on CMH therapy was 9.3 (range, 6.5-14.6) and median duration of CMH was 48 (range, 33-84) days. Mean mitral annular growth was 0.19 ± 0.05 mm/week compared with 0.14 ± 0.05 mm/week in CMH vs controls (mean difference 0.05 ± 0.05 mm/week, P = 0.33). Mean aortic annular growth was 0.14 ± 0.03 mm/week compared with 0.13 ± 0.03 mm/week in CMH vs controls (mean difference 0.01 ± 0.03 mm/week, P = 0.75). More than 9 h CMH daily (n = 6) was associated with better growth of the aortic annulus in intervention fetuses (0.16 ± 0.03 vs 0.08 ± 0.02 mm/week, P = 0.014). CONCLUSIONS: CMH is both safe and feasible for continued research. In this pilot study, the effect estimates of annular growth, using the studied method of delivery and dose of oxygen, were small. Copyright © 2015 ISUOG. Published by John Wiley & Sons Ltd.

Painful dysphagia from infiltrating oat cell carcinoma.

Oat cell carcinoma of the lung is an aggressive malignancy with a propensity for widespread dissemination. Surprisingly, spread of this tumor to the esophagus from adjacent lung is unusual. Although submucosal involvement has been noted occasionally, overt mucosal ulceration, to our knowledge, has not been demonstrated previously. Two patients with oat cell carcinoma developed painful dysphagia and mucosal ulceration from tumor infiltration into the esophagus.

Acute upper gastrointestinal bleeding in patients with portal hypertension: a correlation of endoscopic findings with etiology.

Esophagogastric variceal hemorrhage is a common cause of upper gastrointestinal bleeding in patients with portal hypertension. In addition, it is now recognized that patients with alcohol-induced chronic liver disease and portal hypertension frequently bleed from acute mucosal lesions. Since alcohol can cause these lesions in the absence of portal hypertension, we evaluated 28 episodes of upper gastrointestinal hemorrhage in patients with portal hypertension who did not consume alcohol. Varices were the source of blood loss in 86% of our cases, and no bleeding episodes were attributable to acute mucosal lesions. Acute mucosal lesions, therefore, appear to be uncommon causes of bleeding in nonalcoholic patients with portal hypertension.